Learn about Cannabinol, CBN, Rare Cannabinoids, EB, Glaucoma

Skip to content

Facebook Twitter Linkedin

Pharmaceutical
Manufacturing
Investors
Corporate
Learn

Menu

Pharmaceutical
Manufacturing
Investors
Corporate
Learn

Latest Events

Benzinga Cannabis Capital Conference

Date: Sept. 27-28, 2023

Time: 11:40am CT

Add to Calendar

H.C. Wainwright 25th Annual Global Investment Conference

Date: Sept. 11-13, 2023

Time: 7:00am

Add to Calendar

Investor Summit

Date: June 1, 2023

Time: 11:30am ET

Add to Calendar

Tribe Public Webinar

Date: May 31, 2023

Time: 12:00pm ET

Add to Calendar

Fireside Chat with Water Tower Research

Date: May 23, 2023

Time: 1:00pm ET

Add to Calendar

VirtualInvestorConferences.com – Life Sciences Investor Forum

Date: March 9, 2023

Time: 11:00am ET

Add to Calendar

Management

Board of Directors

Scientific Advisory Board

Investor Alerts

Sign up to receive news releases from InMed Pharmaceuticals.

#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Pharmaceutical

Cannabinoids in Development
INM-755 for Epidermolysis Bullosa
INM-088 for Glaucoma
INM-900 Series for Neurodegenerative Disease
Novel Cannabinoid Analogs

MANUFACTURING

BayMedica – Rare Cannabinoid Ingredients
Cannabinoid Manufacturing Expertise
IntegraSyn™ Cannabinoid Manufacturing

Investor

News
Events
Stock Information
Corporate Governance
Financials & AGM Materials
Filings
Presentations
Media & Videos
Investor Contact

CORPORATE

Management
Board of Directors
Scientific Advisors
Partners and Collaborators
Careers
Contact

Learn

What is Cannabinol (CBN)?
What is Epidermolysis Bullosa (EB)?
What is Glaucoma?
Cannabinoid Manufacturing Economics 101
GMP Manufacturing Standards by Product Type
Cannabinoids for Glaucoma
Cannabinoid Science
Articles and Videos

© Copyright 2023 InMed Pharmaceuticals Inc.

Privacy Policy
Terms of Use
Legal Disclaimer

Find Us On:

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*

First name* Last name*

Email*

Consent*

By providing your e-mail address, you consent to receive news, press releases, quarterly and annual reports, presentations and other information from InMed Pharmaceuticals Inc. You can unsubscribe at any time.

CAPTCHA